Notably, eight proteins upregulated in the invasive stroma (NNMT, FCGR1A, FCER1G, TYMP, F13A1, DCK, CASP3, and SYK) represented FDA-approved drug targets outside of ovarian cancer (Fig. 5I,J), emphasizing their high relevance for future preclinical investigations. This evidence concerns the gene FCGR1A and ovarian cancer.